Comparative Assessment of Clinical Outcomes Between Abiraterone Acetate and Enzalutamide in Patients With Docetaxel-Naive Metastatic Castration-Resistant Prostate Cancer: Experience in Real-World Clinical Practice in Japan

Clinical Genitourinary Cancer

Volumn 15, Issue 2, 2017, Pages 313-319

  Miyake, Hideaki ^a,b   Hara, Takuto ^a   Terakawa, Tomoaki ^a   Ozono, Seiichiro ^b   Fujisawa, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adverse event; AR axis targeted agents; mCRPC; Progression free survival; Response

Indexed keywords

ABIRATERONE ACETATE; DOCETAXEL; ENZALUTAMIDE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER FATIGUE; CANCER GRADING; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL OUTCOME; CLINICAL PRACTICE; CONTROLLED STUDY; DIARRHEA; DRUG TOLERABILITY; HUMAN; HYPERTENSION; JAPANESE (PEOPLE); LIVER TOXICITY; LOSS OF APPETITE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; JAPAN; METASTASIS; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

ABIRATERONE ACETATE; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PHENYLTHIOHYDANTOIN; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84979567684     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2016.06.010     Document Type: Article

References (20)

1. 1 Torre, L.A., Bray, F., Siegel, R.L., et al. Global cancer statistics, 2012. CA Cancer J Clin 65 (2015), 87–108.
2. 2 Chi, K., Hotte, S.J., Joshua, A.M., et al. Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. Ann Oncol 26 (2015), 2044–2056.
3. 3 Fitzpatrick, J.M., Bellmunt, J., Fizazi, K., et al. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer 50 (2014), 1617–1627.
4. 4 Tannock, I.F., de Wit, R., Berry, W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004), 1502–1512.
5. 5 Petrylak, D.P., Tangen, C.M., Hussain, M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004), 1513–1520.
6. 6 Fizazi, K., Scher, H.I., Molina, A., et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13 (2012), 983–992.
7. 7 Ryan, C.J., Smith, M.R., Fizazi, K., et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16 (2015), 152–160.
8. 8 Scher, H.I., Fizazi, K., Saad, F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367 (2012), 1187–1197.
9. 9 Beer, T.M., Armstrong, A.J., Rathkopf, D.E., et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371 (2014), 424–433.
10. 10 Satoh, T., Uemura, H., Tanabe, K., et al. A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy. Jpn J Clin Oncol 44 (2014), 1206–1215.
11. 11 Matsubara, N., Uemura, H., Satoh, T., et al. A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study). Jpn J Clin Oncol 44 (2014), 1216–1226.
12. 12 Yamasaki, M., Yuasa, T., Yamamoto, S., et al. Efficacy and safety profile of enzalutamide for Japanese patients with castration-resistant prostate cancer. Anticancer Res 36 (2016), 361–365.
13. 13 Naito, S., Tsukamoto, T., Koga, H., et al. Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter phase II trial in Japan. Jpn J Clin Oncol 38 (2008), 365–372.
14. 14 Nozawa, M., Mukai, H., Takahashi, S., et al. Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer. Int J Clin Oncol 20 (2015), 1026–1034.
15. 15 Scher, H.I., Halabi, S., Tannock, I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26 (2008), 1148–1159.
16. 16 Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
17. 17 Auchus, R.J., Yu, M.K., Nguyen, S., et al. Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. Oncologist 19 (2014), 1231–1240.
18. 18 Azad, A.A., Eigl, B.J., Leibowitz-Amit, R., et al. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 67 (2015), 441–447.
19. 19 Nadal, R., Zhang, Z., Rahman, H., et al. Clinical activity of enzalutamide in docetaxel-naïve and docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Prostate 74 (2014), 1560–1568.
20. 20 Ravi, P., Mateo, J., Lorente, D., et al. External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone. Eur Urol 66 (2014), 8–11.